Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

3K3A-APC

Drug Profile

3K3A-APC

Alternative Names: 3K3A-activated protein C; 3K3A-APC non-anticoagulant mutant - ZZ Biotech; Activated-protein-C-analogue-University-of-Southern-California/Scripps-Research-Institute/ZZ-Biotech; Human-recombinant-3K3A-APC; Recombinant variant of human activated protein C (3K3A-APC)-ZZ-Biotech

Latest Information Update: 28 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Socratech; The Scripps Research Institute; University of Southern California
  • Developer The Scripps Research Institute; University of Southern California; University of Sydney; ZZ Biotech
  • Class Antithrombotics; Blood proteins; Enzyme precursors; Recombinant proteins; Serine endopeptidases
  • Mechanism of Action Activated protein C receptor modulators; Factor V inhibitors; Factor VIII inhibitors; PAR 1 receptor modulators; PAR-3 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Stroke
  • Preclinical Diabetic foot ulcer
  • No development reported Amyotrophic lateral sclerosis; Neurological disorders; Septic shock

Most Recent Events

  • 28 Dec 2018 No recent reports of development identified for phase-I development in Stroke(In volunteers) in Austria (IV, Infusion)
  • 28 Dec 2018 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA (IV)
  • 28 Dec 2018 No recent reports of development identified for preclinical development in Neurological-disorders in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top